tetano
Editor, Senior Moderator
Pediatrics
. 2022 Mar 28;e2021055432.
doi: 10.1542/peds.2021-055432. Online ahead of print.
Safety of Live Attenuated Influenza Vaccine in Children With Asthma
Andrew G Sokolow[SUP] #[/SUP][SUP] 1 2 [/SUP], Amy P Stallings[SUP] #[/SUP][SUP] 3 4 [/SUP], Carolyn Kercsmar[SUP] 5 [/SUP], Theresa Harrington[SUP] 6 [/SUP], Natalia Jimenez-Truque[SUP] 7 [/SUP], Yuwei Zhu[SUP] 8 [/SUP], Katherine Sokolow[SUP] 2 7 [/SUP], M Anthony Moody[SUP] 4 9 [/SUP], Elizabeth P Schlaudecker[SUP] 5 [/SUP], Emmanuel B Walter[SUP] 4 9 [/SUP], Mary Allen Staat[SUP] 5 [/SUP], Karen R Broder[SUP] 6 [/SUP], C Buddy Creech[SUP] 7 [/SUP]
Affiliations
Abstract
Background and objectives: Asthma is considered a precaution for use of quadrivalent live attenuated influenza vaccine (LAIV4) in persons aged ≥5 years because of concerns for wheezing events. We evaluated the safety of LAIV4 in children with asthma, comparing the proportion of children with asthma exacerbations after LAIV4 or quadrivalent inactivated influenza vaccine (IIV4).
Methods: We enrolled 151 children with asthma, aged 5 to 17 years, during 2 influenza seasons. Participants were randomly assigned 1:1 to receive IIV4 or LAIV4 and monitored for asthma symptoms, exacerbations, changes in peak expiratory flow rate (PEFR), and changes in the asthma control test for 42 days after vaccination.
Results: We included 142 participants in the per-protocol analysis. Within 42 days postvaccination, 18 of 142 (13%) experienced an asthma exacerbation: 8 of 74 (11%) in the LAIV4 group versus 10 of 68 (15%) in the IIV4 group (LAIV4-IIV4 = -0.0390 [90% confidence interval -0.1453 to 0.0674]), meeting the bounds for noninferiority. When adjusted for asthma severity, LAIV4 remained noninferior to IIV4. There were no significant differences in the frequency of asthma symptoms, change in PEFR, or childhood asthma control test/asthma control test scores in the 14 days postvaccination between LAIV4 and IIV4 recipients. Vaccine reactogenicity was similar between groups, although sore throat (P = .051) and myalgia (P <.001) were more common in the IIV4 group.
Conclusions: LAIV4 was not associated with increased frequency of asthma exacerbations, an increase in asthma-related symptoms, or a decrease in PEFR compared with IIV4 among children aged 5 to 17 years with asthma.
. 2022 Mar 28;e2021055432.
doi: 10.1542/peds.2021-055432. Online ahead of print.
Safety of Live Attenuated Influenza Vaccine in Children With Asthma
Andrew G Sokolow[SUP] #[/SUP][SUP] 1 2 [/SUP], Amy P Stallings[SUP] #[/SUP][SUP] 3 4 [/SUP], Carolyn Kercsmar[SUP] 5 [/SUP], Theresa Harrington[SUP] 6 [/SUP], Natalia Jimenez-Truque[SUP] 7 [/SUP], Yuwei Zhu[SUP] 8 [/SUP], Katherine Sokolow[SUP] 2 7 [/SUP], M Anthony Moody[SUP] 4 9 [/SUP], Elizabeth P Schlaudecker[SUP] 5 [/SUP], Emmanuel B Walter[SUP] 4 9 [/SUP], Mary Allen Staat[SUP] 5 [/SUP], Karen R Broder[SUP] 6 [/SUP], C Buddy Creech[SUP] 7 [/SUP]
Affiliations
- PMID: 35342923
- DOI: 10.1542/peds.2021-055432
Abstract
Background and objectives: Asthma is considered a precaution for use of quadrivalent live attenuated influenza vaccine (LAIV4) in persons aged ≥5 years because of concerns for wheezing events. We evaluated the safety of LAIV4 in children with asthma, comparing the proportion of children with asthma exacerbations after LAIV4 or quadrivalent inactivated influenza vaccine (IIV4).
Methods: We enrolled 151 children with asthma, aged 5 to 17 years, during 2 influenza seasons. Participants were randomly assigned 1:1 to receive IIV4 or LAIV4 and monitored for asthma symptoms, exacerbations, changes in peak expiratory flow rate (PEFR), and changes in the asthma control test for 42 days after vaccination.
Results: We included 142 participants in the per-protocol analysis. Within 42 days postvaccination, 18 of 142 (13%) experienced an asthma exacerbation: 8 of 74 (11%) in the LAIV4 group versus 10 of 68 (15%) in the IIV4 group (LAIV4-IIV4 = -0.0390 [90% confidence interval -0.1453 to 0.0674]), meeting the bounds for noninferiority. When adjusted for asthma severity, LAIV4 remained noninferior to IIV4. There were no significant differences in the frequency of asthma symptoms, change in PEFR, or childhood asthma control test/asthma control test scores in the 14 days postvaccination between LAIV4 and IIV4 recipients. Vaccine reactogenicity was similar between groups, although sore throat (P = .051) and myalgia (P <.001) were more common in the IIV4 group.
Conclusions: LAIV4 was not associated with increased frequency of asthma exacerbations, an increase in asthma-related symptoms, or a decrease in PEFR compared with IIV4 among children aged 5 to 17 years with asthma.